Table 3.
Summary of patients who died during the 5 year follow up period
| Patient # | Group | Cause of death |
|---|---|---|
| 1 | Placebo | cardiogenic shock |
| 2 | Placebo | cardiogenic shock |
| 3 | EPO | lung embolism |
| 4 | Placebo | sudden cardiac death |
| 5 | EPO | septic shock, stroke |
| 6 | EPO | cancer |
| 7 | Placebo | after orthopedic surgery |
| 8 | EPO | sudden cardiac death |
| 9 | EPO | unknown |
| 10 | Placebo | cancer |
| 11 | EPO | sudden cardiac death |
| 12 | Placebo | unknown |
| 13 | EPO | unknown |
| 14 | EPO | unknown |
Patient # 1–5 died 1–186 days after randomization. Patient # 7–14 died 187–1860 days after randomization